![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Maraviroc Pharmacokinetics and Dosing Recommendations in CCR5-Tropic HIV-1-Infected Children Aged 2 to <18 Years
|
|
|
Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
Vourvahis M,1McFadyen L,2Valluri SR,1Fang A,1 Moore K,3Heera J4
1Pfizer, New York, NY, USA; 2Pfizer, Sandwich, Kent, UK; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4Pfizer, Groton, CT, USA
![0906171](../images/090617/090617-15/0906171.gif)
![0906172](../images/090617/090617-15/0906172.gif)
![0906173](../images/090617/090617-15/0906173.gif)
![0906174](../images/090617/090617-15/0906174.gif)
![0906175](../images/090617/090617-15/0906175.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|